文献速递血栓与止血

艾曲泊帕作为血小板生成素模拟物可穿过血脑屏障并损害依赖铁的海马神经元树突发育

Eltrombopag, a thrombopoietin mimetic, crosses the blood-brain barrier and impairs iron-dependent hippocampal neuron dendrite development.
PubMed 文献 · J Thromb Haemost · 2017-02-16

研究评估艾曲泊帕(ELT)能否穿过血脑屏障、导致神经元铁缺乏并损害海马神经元树突成熟。ELT以时间依赖方式穿过血脑屏障,2和6 μM ELT升高Tfr1和Slc11a2 mRNA水平提示神经元铁缺乏,6 μM ELT降低BdnfVI、Camk2a和Vamp1 mRNA并减少树突分支数目和长度。结论认为发育期ELT治疗可能因神经元铁缺乏损害神经元结构,需临床前体内研究评估安全性。

要点

  • ELT以时间依赖方式穿过血脑屏障。
  • 2和6 μM ELT升高Tfr1和Slc11a2 mRNA水平,提示神经元铁缺乏。
  • 6 μM ELT降低BdnfVI、Camk2a和Vamp1 mRNA并减少树突分支数目和长度。

核心结论

  • 发育期艾曲泊帕治疗可能因神经元铁缺乏而损害神经元结构。
  • 需临床前体内研究评估艾曲泊帕在脑快速发育期的安全性。

研究设计与样本

  • 采用原代牛脑微血管内皮细胞评估ELT跨血脑屏障转运。
  • 胚胎小鼠原代海马神经元培养自体外7天至14天给予ELT或去铁胺(DFO,铁螯合剂),评估基因表达和神经元树突复杂性。

主要发现

  • ELT以时间依赖方式穿过血脑屏障。
  • 2和6 μM ELT升高Tfr1和Slc11a2 mRNA水平,提示神经元铁缺乏。
  • 6 μM而非2 μM ELT降低BdnfVI、Camk2a和Vamp1 mRNA水平,提示神经元发育和突触功能受损。
  • 6 μM ELT处理神经元树突分支数目和长度减少,树突arbor复杂性减弱,与DFO处理神经元相似。

临床怎么用

  • 作者认为发育期艾曲泊帕治疗可能因神经元铁缺乏损害神经元结构。
  • 作者提出需临床前体内研究评估艾曲泊帕在脑快速发育期的安全性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Potential neurodevelopmental side effects of thrombopoietin mimetics need to be considered. The effects of eltrombopag (ELT) on neuronal iron status and dendrite development were assessed. ELT crosses the blood-brain barrier and causes iron deficiency in developing neurons. ELT blunts dendrite maturation, indicating a need for more safety studies before neonatal use. SUMMARY: Background Thrombocytopenia is common in sick neonates. Thrombopoietin mimetics (e.g. eltrombopag [ELT]) might provide an alternative therapy for selected neonates with severe and prolonged thrombocytopenia, and for infants and young children with different varieties of thrombocytopenia. However, ELT chelates intracellular iron, which may adversely affect developing organs with high metabolic requirements. Iron deficiency (ID) is particularly deleterious during brain development, impairing neuronal myelination, dopamine signaling and dendritic maturation and ultimately impairing long-term neurological function (e.g. hippocampal-dependent learning and memory). Objective To determine whether ELT crosses the blood-brain barrier (BBB), causes neuronal ID and impairs hippocampal neuron dendrite maturation. Methods ELT transport across the BBB was assessed using primary bovine brain microvascular endothelial cells. Embryonic mouse primary hippocampal neuron cultures were treated with ELT or deferoxamine (DFO, an iron chelator) from 7 days in vitro (DIV) through 14 DIV and assessed for gene expression and neuronal dendrite complexity. Results ELT crossed the BBB in a time-dependent manner. 2 and 6 μm ELT increased Tfr1 and Slc11a2 (iron-responsive genes involved in neuronal iron uptake) mRNA levels, indicating neuronal ID. 6 μm ELT, but not 2 μm ELT, decreased BdnfVI, Camk2a and Vamp1 mRNA levels, suggesting impaired neuronal development and synaptic function. Dendrite branch number and length were reduced in 6 μm ELT-treated neurons, resulting in blunted dendritic arbor complexity that was similar to DFO-treated neurons. Conclusions Eltrombopag treatment during development may impair neuronal structure as a result of neuronal ID. Preclinical in vivo studies are warranted to assess ELT safety during periods of rapid brain development.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Bastian TW, Duck KA, Michalopoulos GC, et al. Eltrombopag, a thrombopoietin mimetic, crosses the blood-brain barrier and impairs iron-dependent hippocampal neuron dendrite development. J Thromb Haemost. 2017. PMID: 28005311. doi:10.1111/jth.13602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。